Information Provided By:
Fly News Breaks for January 11, 2017
SRPT
Jan 11, 2017 | 07:54 EDT
RBC Capital analyst Simos Simeonidis notes that Sarepta reported that it only obtained revenue of $5.4M from its EXONDYS 51 in the wake of its launch. However, the analyst is "encouraged by the disclosure that 250 forms have been filled out for patients whose mutation status has been verified" as of the end of last year. Simeonidis continues to predict that the drug will undergo a "slow and gradual ramp," with its sales accelerating significantly in the "later" quarters of this year. The analyst keeps a $98 price target and an Outperform rating on the stock.
News For SRPT From the Last 2 Days
There are no results for your query SRPT